Name | Type | Posted | Actions |
|---|---|---|---|
RRPV-26-13-BundiVx_RPP_Finalv2.docx | DOCX | Jun 11, 2026 |
Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium
Contact and place of performance
Veronica Stroud
Washington, DC 20024
USA
The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows: The purp...
View moreThe end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development.
Please see the attachments for more information.
Questions are due June 16, 2026 by 12 p.m. Eastern. Proposals are due by June 26 at 3 p.m. Eastern.
Submission link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/
The Administration for Strategic Preparedness and Response (ASPR), through the Office of Biomedical Advanced Research and Development Authority (BARDA), issued solicitation RRPV-26-13-BundiVx to advance investigational Bundibugyo virus (BDBV) vaccine candidates. This effort utilizes the Rapid Response Partnership Vehicle (RRPV) Consortium to leverage the VSV vaccine platform for manufacturing process development and the production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material. The project is classified under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) and PSC AN23 Health R&D Services; Health Research and Training; Experimental Development. The primary objectives are to produce up to 10,000 doses for the ongoing 2026 BDBV outbreak and to identify successful candidates for further development. There is no set-aside designated for this requirement, listed as Set-aside NONE.
The scope of work includes early regulatory engagement to inform IND-enabling nonclinical studies and a Phase 1 safety and immunogenicity trial. Proposed approaches must utilize platform efficiencies from previous or ongoing development to accelerate the path toward IND submission and clinical trial material production. The initiative also includes options for the production of up to 100,000 doses of cGMP material. Performance is located in Washington, DC, under the management of point of contact Veronica Stroud.
The deadline for questions is June 16, 2026, with final proposals due by 3 p.m. Eastern on June 26, 2026. This solicitation, published on June 11, 2026, includes one attachment titled RRPV-26-13-BundiVx_RPP_Finalv2.docx. All research and development activities are intended to facilitate a rapid response through the collaboration of industry and academia within the RRPV enterprise partnership.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.